PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.07
0.06 - 0.24
1.89M / 3.59M (Avg.)
-1.60 | -0.04
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-5.58%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
-12.78%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
46.64%
Positive growth while CRN.AX shows decline. John Neff would investigate competitive advantages.
55.30%
Margin expansion while CRN.AX shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.63%
Operating expenses growth while CRN.AX reduces costs. John Neff would investigate differences.
-10.95%
Both companies reducing total costs. Martin Whitman would check industry trends.
-100.00%
Interest expense reduction while CRN.AX shows 0.00% growth. Joel Greenblatt would examine advantage.
21.94%
D&A growth while CRN.AX reduces D&A. John Neff would investigate differences.
105.79%
EBITDA growth exceeding 1.5x CRN.AX's 6.09%. David Dodd would verify competitive advantages.
117.96%
EBITDA margin growth while CRN.AX declines. John Neff would investigate advantages.
90.24%
Operating income growth while CRN.AX declines. John Neff would investigate advantages.
101.48%
Operating margin growth while CRN.AX declines. John Neff would investigate advantages.
26.87%
Other expenses growth less than half of CRN.AX's 71.85%. David Dodd would verify if advantage is sustainable.
126.48%
Pre-tax income growth exceeding 1.5x CRN.AX's 55.66%. David Dodd would verify competitive advantages.
128.04%
Pre-tax margin growth exceeding 1.5x CRN.AX's 25.90%. David Dodd would verify competitive advantages.
251.28%
Tax expense growth while CRN.AX reduces burden. John Neff would investigate differences.
153.85%
Net income growth exceeding 1.5x CRN.AX's 47.33%. David Dodd would verify competitive advantages.
157.03%
Net margin growth exceeding 1.5x CRN.AX's 11.99%. David Dodd would verify competitive advantages.
154.17%
EPS growth exceeding 1.5x CRN.AX's 47.22%. David Dodd would verify competitive advantages.
154.17%
Diluted EPS growth exceeding 1.5x CRN.AX's 47.31%. David Dodd would verify competitive advantages.
-0.57%
Both companies reducing share counts. Martin Whitman would check patterns.
-0.57%
Diluted share reduction while CRN.AX shows 0.00% change. Joel Greenblatt would examine strategy.